Edition:
United States

People: AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

4,033.50GBp
5 Dec 2016
Change (% chg)

-21.50p (-0.53%)
Prev Close
4,055.00p
Open
4,027.50p
Day's High
4,082.00p
Day's Low
4,019.00p
Volume
2,437,237
Avg. Vol
2,908,704
52-wk High
5,505.00p
52-wk Low
3,680.00p

Jallal, Bahija 

Dr. Bahija Jallal, Ph.D. is the Executive Vice President, MedImmune of AstraZeneca PLC., since January 2013 and is responsible for biologics research activities. Bahija is tasked with advancing the biologic pipeline of drugs. She joined MedImmune in 2006 as Vice-President, Translational Sciences and has held roles of increasing responsibility at AstraZeneca. Prior to joining AstraZeneca, Bahija worked with Chiron Corporation where she served as Vice-President, Drug Assessment and Development. Bahija received a master’s degree in biology from the Université de Paris VII and her doctorate in physiology from the Université Pierre et Marie Curie, Paris. She conducted her post-doctoral research at the Max-Planck Institute of Biochemistry in Martinsried, Germany. She is a member of the American Association of Cancer Research, the American Association of Science, the Pharmacogenomics Working Group and the Board of Directors of the Association of Women in Science.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Awards, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Leif Johansson

609,000

Pascal Soriot

8,397,000

Marc Dunoyer

5,955,000

Fiona Cicconi

--

Sean Bohen

--

Pam Cheng

--
As Of  30 Dec 2015